sEH-IN-24 是一种具有口服活性的可溶性环氧化物水解酶 (sEH) 抑制剂(IC50 为 1.9 nM),可抑制促炎性细胞因子 TNF-α 和 IL-6,具有抗炎作用及体内镇痛作用,可预防胰腺水肿、炎症及实质萎缩,并可用于急性胰腺炎的研究。
产品编号: MS-W98265 CAS No.: 3121405-85-1 分子式: C28H39NO6 分子量: 485.61
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
50mg
询价
询价
100mg
询价
询价
250mg
询价
询价

产品描述

sEH-IN-24 是一种具有口服活性的可溶性环氧化物水解酶 (sEH) 抑制剂(IC50 为 1.9 nM),可抑制促炎性细胞因子 TNF-α 和 IL-6,具有抗炎作用及体内镇痛作用,可预防胰腺水肿、炎症及实质萎缩,并可用于急性胰腺炎的研究。

生物实验数据

生物活性 sEH-IN-24 is an orally active soluble epoxide hydrolase (sEH) inhibitor with an IC50 of 1.9 nM that inhibits the pro-inflammatory cytokines TNF-α and IL-6, exhibits anti-inflammatory effects and in vivo analgesic activity, prevents pancreatic edema, inflammation, and parenchymal atrophy, and can be used for the study of acute pancreatitis.
IC50 & Target

IL-6

 

sEH

1.9 nM (IC50)

体外研究
(In Vitro)

sEH-IN-24 (Compound (+)-34) (0.46-1000 nM) 可强效抑制 sEH,其 IC50 为 1.9 nM,能与关键活性位点残基形成稳定相互作用,并在与该酶形成复合物时保持动态稳定性。
sEH-IN-24 对 293-T、HL7702 和 MIHA 正常细胞系的细胞毒性较低,其 GI50 值 >100 μM。
sEH-IN-24 (0.25-8 μM) 可强效抑制 LPS 诱导的 RAW 264.7 和 THP-1 巨噬细胞中 IL-6 与 TNF-α 的释放,其 IC50 值范围为 0.7 至 1.3 μM。

体内研究
(In Vivo)

sEH-IN-24 (5-20 mg/kg;口服;腹腔注射;单次) 在角叉菜胶诱导的小鼠爪水肿模型中表现出持续的、剂量依赖性的抗炎活性,可提升血浆抗炎 EET/DHET 比值,口服给予后 2 h 时的抑制峰值为 37.3%。
sEH-IN-24 (5-10 mg/kg;口服;单次) 在小鼠醋酸诱导扭体模型中表现出强效的、剂量依赖性口服镇痛活性,在 10 mg/kg 剂量下可使扭体次数减少 45%。
sEH-IN-24 (10 mg/kg;腹腔注射;首次雨蛙素注射后 0.5 h 和 2.5 h 各给予一次) 在雨蛙素诱导的小鼠急性胰腺炎模型中展现出显著的治疗活性,可使胰腺组织病理学评分降低 56.3%,下调促炎细胞因子水平,并升高胰腺组织及血浆中抗炎性 EET/DHET 比值。

Animal Model: C57BL/6J (male, 23−25 g, 6−8 weeks old)
Dosage: 20 mg/kg (p.o.); 10 mg/kg (p.o.); 10 mg/kg (i.p.); 5 mg/kg (i.p.)
Administration: p.o.; single dose; i.p.; single dose
Result: Achieved a paw edema inhibition rate of 37.3% at 2 h post-administration, which remained stable at 31.6% 4 h post-peak efficacy.
Increased plasma 8,9-EET/DHET by 219% and 14,15-EET/DHET by 274% relative to the model group, alongside elevations in 8,9-EET (81.1%) and 14,15-EET (108%) levels, and reductions in 8,9-DHET (17.3%) and 14,15-DHET (23.9%) levels at 20 mg/kg (p.o.).
Increased plasma 8,9-EET/DHET by 315%, 11,12-EET/DHET by 198%, and 14,15-EET/DHET by 308% relative to the model group, alongside elevations in 8,9-EET (56.8%), 11,12-EET (60.4%), and 14,15-EET (121%) levels, and reductions in 8,9-DHET (50.0%), 11,12-DHET (18.9%), and 14,15-DHET (28.2%) levels at 10 mg/kg (i.p.).
Animal Model: C57BL/6J (male, 23−25 g, 6−8 weeks old)
Dosage: 10 mg/kg; 5 mg/kg
Administration: p.o.; single dose
Result: Reduced the number of writhing episodes by 45% relative to the model group at 10 mg/kg (p.o.).
Significantly reduced writhing episodes at 5 mg/kg (p.o.), with activity showing a concentration-dependent correlation.
Animal Model: C57BL/6J (male, 23−25 g, 6−8 weeks old)
Dosage: 10 mg/kg
Administration: i.p.; two doses at 0.5 h and 2.5 h post-first cerulein injection
Result: Reduced total pancreatic histopathological scores by 56.3% relative to the model group, alleviating edema, inflammatory infiltration, and parenchymal atrophy.
Reduced plasma TNF-α levels by 46.8% and IL-6 levels by 67.1% relative to the model group.
Increased pancreatic tissue 8,9-EET/DHET by 424%, 11,12-EET/DHET by 1476%, and 14,15-EET/DHET by 2180% relative to the model group.
Increased plasma 11,12-EET/DHET by 86% and 14,15-EET/DHET by 111% relative to the model group.
Animal Model: C57BL/6J (male, 8 weeks old)
Dosage: 20 mg/kg
Administration: p.o.; single dose
Result: Achieved a plasma Cmax of 10,127 ng/mL and AUC0-24h of 148,683 h·ng/mL.
Achieved a liver Cmax of 36,378 ng/g and AUC0-24h of 468,142 h·ng/g.
Achieved a kidney Cmax of 27,061 ng/g and AUC0-24h of 306,849 h·ng/g.
Achieved a brain Cmax of 1021 ng/g and AUC0-24h of 9127 h·ng/g.
Tissue-to-plasma Cmax ratios were 3.59 (liver), 2.67 (kidney), and 0.101 (brain).
Tissue-to-plasma AUC0-24h ratios were 3.15 (liver), 2.06 (kidney), and 0.061 (brain).
Animal Model: Sprague-Dawley (SD) (male, 200 g)
Dosage: 20 mg/kg (p.o.); 5 mg/kg (i.v.)
Administration: p.o.; single dose; i.v.; single dose
Result: After oral administration, had a Tmax of 2.08 h, Cmax of 2064 ng/mL, AUC0-24h of 17834 h·ng/mL, half-life of 2.38 h, volume of distribution of 4017 mL/kg, systemic clearance of 1308 mL/h/kg, and bioavailability of 22.1%.
After intravenous administration, had a Tmax of 0.09 h, Cmax of 7985 ng/mL, AUC0-24h of 20144 h·ng/mL, half-life of 2.21 h, volume of distribution of 896 mL/kg, and systemic clearance of 273 mL/h/kg.

化学信息

分子量 485.61
分子式 C28H39NO6
CAS No. 3121405-85-1

储存&溶解度

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

运输条件 Room temperature in continental US; may vary elsewhere.

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础